SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT03911440

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Diagnosis and Treatment of Mycoplasma Pneumoniae and Vaccine Development

A randomized clinical trial comparing treatment effectiveness of azithromycin and doxycycline for pediatric Mycoplasma pneumonia.

NCT03911440 Atypical Pneumonia
MeSH:Mycoplasma Infections Pneumonia, Mycoplasma Pneumonia Pleuropneumonia

2 Interventions

Name: Doxycycline

Description: Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
Type: Drug
Group Labels: 1


Name: Azithromycin

Description: Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
Type: Drug
Group Labels: 1


Primary Outcomes

Description: The timing (days) when fever subsides after treatment

Measure: Defervescence

Time: Up to 10 days

Secondary Outcomes

Description: The length of hospitalization

Measure: Hospital stay

Time: Up to 2 weeks

Purpose: Treatment

Allocation: Randomized

Parallel Assignment

There is one SNP


1 A2063G

In previous studies, the most common mutation point, A2063G, was detected from 23% of local strains in Taiwan. --- A2063G ---

HPO Nodes